The premature commercialization of new therapies threatens the development of scientifically validated treatments and places unnecessary economic burdens on healthcare systems and the public. When new products are sold to patients before their effectiveness is thoroughly tested, government and private healthcare payers are often compelled to reimburse for the products without knowing whether they work, and physicians with inadequate expertise are left on their own to evaluate the safety and efficacy of products for individual patients.
In the stem cell field, the premature commercialization of stem cell-based interventions has led to patients being paralyzed and blinded. We encourage you to strengthen the governance framework by emphasizing the need to ensure that all new products are proven safe and effective."
Read the letter.